Gobind Singh
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,711
Out of 4,711 analysts
9
Total ratings
6.67%
Success rate
-56.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gobind Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Assumes: Buy | $35 | $14.55 | +140.55% | 1 | Sep 19, 2022 | |
| ELEV Elevation Oncology | Assumes: Buy | $7.5 | $0.58 | +1,193.10% | 1 | Sep 19, 2022 | |
| IMUX Immunic | Assumes: Buy | $26 | $1.00 | +2,500.00% | 2 | Sep 19, 2022 | |
| PRTA Prothena Corporation | Initiates: Market Outperform | $77 | $15.22 | +405.91% | 1 | Nov 19, 2021 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $60 → $70 | $41.49 | +68.72% | 4 | Nov 15, 2021 |
AnaptysBio
Sep 19, 2022
Assumes: Buy
Price Target: $35
Current: $14.55
Upside: +140.55%
Elevation Oncology
Sep 19, 2022
Assumes: Buy
Price Target: $7.5
Current: $0.58
Upside: +1,193.10%
Immunic
Sep 19, 2022
Assumes: Buy
Price Target: $26
Current: $1.00
Upside: +2,500.00%
Prothena Corporation
Nov 19, 2021
Initiates: Market Outperform
Price Target: $77
Current: $15.22
Upside: +405.91%
Protagonist Therapeutics
Nov 15, 2021
Maintains: Market Outperform
Price Target: $60 → $70
Current: $41.49
Upside: +68.72%